There are 2789 resources available
824TiP - An open-label, single arm, phase II trial of niraparib in combination with anti-PD1 antibody in recurrent/advanced stage endometrial cancer patients
Presenter: Jundong Li
Session: ePoster Display
Resources:
Abstract
834P - Role of assessment of IL-6, IL-15 and soluble PD-L1 levels as prognostic and predictive biomarkers in nivolumab-treated relapsed/refractory Hodgkin lymphoma
Presenter: Andrey Chekalov
Session: ePoster Display
835P - Enhancement of the International Prognostic Index with hematologic parameters: A new prognostic model for diffuse large B-cell lymphoma treated with R-CHOP
Presenter: Haizhu Chen
Session: ePoster Display
836P - Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: A Hong Kong population-based study
Presenter: Shing Fung Lee
Session: ePoster Display
837P - Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience
Presenter: Salman Soomar
Session: ePoster Display
839P - Physician considered treatment attributes for third-line diffuse-large B-cell lymphoma treatment decision-making: Physician perspectives from a survey across Western Europe and US
Presenter: Patrick Connor Johnson
Session: ePoster Display
906P - Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck
Presenter: Aaron Hansen
Session: ePoster Display
842P - Secreted factors determine resistance to idelalisib in splenic marginal zone lymphoma (MZL) models
Presenter: Alberto Arribas
Session: ePoster Display
843P - Characteristics and outcomes of ocular adnexal lymphomas: Experience of a tertiary cancer care center over 16 years
Presenter: Inês Oliveira
Session: ePoster Display